Peking Union Medical College Hospital: Carcinoma, Hepatocellular trials

The registry lists 23 Carcinoma, Hepatocellular studies with Peking Union Medical College Hospital as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 11No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 68Ga-NYM207 PET/CT Imaging in Hepatocellular CarcinomaRecruitingNCT07590336Phase 1/2
• β-alanine in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07317414Phase 2
• ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingNCT07157969Phase 2
• An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.RecruitingNCT07101237
• Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular CarcinomaRecruitingNCT07014150Phase 2
• The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular CarcinomaNot yet recruitingNCT06750159
• Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular CancerRecruitingNCT06363006Phase 1
• Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT06215651Phase 2
• Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver TransplantationNot yet recruitingNCT06041490Phase 2
• A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05981066Not applicable
• Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
• Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor MicroenvironmentActive, not recruitingNCT07437859
• Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B PopulationActive, not recruitingNCT06379334
• Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT05536427Phase 1
• Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknownNCT05339321Phase 1
• Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular CarcinomaStatus unknownNCT05161143Phase 2
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
• Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
• 18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular CarcinomaStatus unknownNCT02238769
• Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.Status unknownNCT02036216
• Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT ScanStatus unknownNCT01350726
• A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor MarkStatus unknownNCT00902902